LTRN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Lantern Pharma Inc (LTRN) is not a strong buy for a beginner investor with a long-term focus at this time. The technical indicators are bearish, the financial performance shows no revenue growth and worsening losses, and there are no strong positive catalysts or trading signals to support an immediate buy decision. Holding off for now is recommended.
The technical indicators for LTRN are bearish. The MACD histogram is negative (-0.0357) and contracting, RSI is neutral at 33.987, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 2.884, with support at 2.604 and resistance at 3.165.
Lantern Pharma is leveraging its RADR® platform to optimize clinical trials and drug development. The company has also established Starlight Therapeutics to focus on CNS cancers, which could enhance its market presence. Additionally, the CEO's upcoming presentation at the Glioblastoma Drug Development Summit may generate interest.
The company's financial performance is weak, with no revenue growth and increasing losses (-7.29% YoY drop in net income). The technical indicators are bearish, and there is no significant insider or hedge fund activity. The stock has a 60% chance of declining in the next day and limited upside in the short term.
In Q3 2025, Lantern Pharma reported no revenue growth (0% YoY), a net income loss of -$4.18M (-7.29% YoY), and an EPS of -0.39 (-7.14% YoY). The gross margin remains at 0%.
No recent analyst rating or price target changes are available for LTRN.
